Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer-Reference-Cited by-同舟云学术

Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer

Published:2019-07 Issue:1 Volume:36 Page:35-50.e9
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Woolston Andrew,Khan Khurum,Spain Georgia,Barber Louise J.,Griffiths Beatrice,Gonzalez-Exposito Reyes,Hornsteiner Lisa,Punta Marco,Patil Yatish,Newey Alice,Mansukhani Sonia,Davies Matthew N.,Furness Andrew,Sclafani Francesco,Peckitt Clare,Jiménez Mirta,Kouvelakis Kyriakos,Ranftl Romana,Begum Ruwaida,Rana Isma,Thomas Janet,Bryant Annette,Quezada Sergio,Wotherspoon Andrew,Khan Nasir,Fotiadis Nikolaos,Marafioti Teresa,Powles Thomas,Lise Stefano,Calvo Fernando,Guettler Sebastian,von Loga Katharina,Rao Sheela,Watkins David,Starling Naureen,Chau Ian,Sadanandam Anguraj,Cunningham David,Gerlinger Marco

Funder

Wellcome Trust

Cancer Research UK

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference100 articles.

1. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015;Allegra;J. Clin. Oncol.,2016

2. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer;Amado;J. Clin. Oncol.,2008

3. Evolution of metastases in space and time under immune selection;Angelova;Cell,2018

4. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer;Arena;Clin. Cancer Res.,2015

Cited by 174 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic and non‐genetic drug resistance: Darwin or Lamarck?;Molecular Oncology;2024-02-02

2. Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer;Cancers;2024-01-18

3. Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell cancer;Therapeutic Advances in Medical Oncology;2024-01

4. Analysis of translesion polymerases in colorectal cancer cells following cetuximab treatment: A network perspective;Cancer Medicine;2024-01

5. Stress-induced Rab11a-exosomes induce AREG-mediated cetuximab resistance in colorectal cancer;2023-12-20